New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma

Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab-bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.

Automated summary

The combination of CAR T cells with Pembrolizumab demonstrates efficacy in cold solid tumors with low genomic heterogeneity, while Atezolizumab-Bevacizumab combination offers a straightforward approach of antiangiogenics and immunotherapy for orphan diseases.